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Abstract 23
Current clinical genomics assays primarily utilize short-read sequencing (SRS), which offers high throughput, high 24 base accuracy, and low cost per base. SRS has, however, limited ability to evaluate tandem repeats, regions with 25 high [GC] or [AT] content, highly polymorphic regions, highly paralogous regions, and large-scale structural 26 variants. Long-read sequencing (LRS) has complementary strengths and offers a means to discover overlooked 27 genetic variation in patients undiagnosed by SRS. To evaluate LRS, we selected a patient who presented with 28 multiple neoplasia and cardiac myxomata suggestive of Carney complex for whom targeted clinical gene testing and 29 whole genome SRS were negative. Low coverage whole genome LRS was performed on the PacBio Sequel system 30 and structural variants were called, yielding 6,971 deletions and 6,821 insertions > 50bp. Filtering for variants that 31 are absent in an unrelated control and that overlap a coding exon of a disease gene identified three deletions and 32 three insertions. One of these, a heterozygous 2,184 bp deletion, overlaps the first coding exon of PRKAR1A, which 33 is implicated in autosomal dominant Carney complex. This variant was confirmed by Sanger sequencing and was 34 classified as pathogenic using standard criteria for the interpretation of sequence variants. This first successful 35 application of whole genome LRS to identify a pathogenic variant suggests that LRS has significant potential to 36 identify disease-causing structural variation. We recommend larger studies to evaluate the diagnostic yield of LRS, 37 and the development of a comprehensive catalog of common human structural variation to support future studies. 38 39 3 Short-read sequencing (SRS) methods are currently favored in clinical medicine because of their cost effectiveness 40 and low per-base error rate. However, these methods are limited in their ability to capture the full range of genomic 41 variation. 1 Areas of low complexity such as repeats and areas of high polymorphism, such as the HLA region, 42 present challenges to SRS and reference-based genome assembly. Indeed, with 100 base pair (bp) read length, fully 43 5% of the genome cannot be uniquely mapped. 2 In addition, many diseases are caused by repeats that become 44 increasingly pathogenic in a range beyond the resolution of SRS. Another challenge comes in the form of structural 45 variation, and while SRS has been very successful in the genetic discovery of single nucleotide and small insertion-46 deletion variation, recent findings suggest we have greatly underestimated the extent and complexity of structural 47 variation in the genome. 3,4 48
Long-read sequencing (LRS), typified by PacBio® single molecule, real-time (SMRT®) sequencing, offers 49 complementary strengths to SRS. PacBio LRS produces reads of several thousand base pairs with uniform coverage 50 across sequence contexts. 5 Individual long reads have a lower accuracy (85%) than short reads, but errors are 51 random and are correctable with sufficient coverage, leading to extremely high consensus accuracy. 5,6 Further, long 52 reads are more accurately mapped to the genome and access regions that are beyond the reach of short reads. 1 Of 53 particular note, recent PacBio LRS de novo human genome assemblies have revealed tens of thousands of structural 54 variants per genome, many times more than previously observed with SRS. 3,7 These capabilities, together with 55 continuing progress in throughput and cost, have begun to make LRS an option for broader application in human 56
genomics. 57
Here, we report the use of low coverage whole genome PacBio LRS to secure a diagnosis of Carney complex in a 58 patient unsolved by clinical single gene testing and whole genome SRS. The patient is an Asian/Hispanic male, the 59 product of an uncomplicated term pregnancy who was hospitalized for the first 10 days of life for cardiac and 60 respiratory issues ( Figure 1A) . He remained well until the age of 7 years, when, following the discovery of a heart 61 murmur, he was found to have a left atrial myxoma that was surgically removed. At 10 years, he was noted to have a 62 testicular mass that, at orchiectomy, was found to be a Sertoli-Leydig cell tumor. At 13 years, a pituitary tumor was 63 found and initial conservative management was adopted. Aged 16, he was noted to have both an adrenal 64 microadenoma and recurrence of the cardiac myxomata in the left ventricle and right atrium. Blue naevi were 65 reported. He underwent a second surgical resection of the myxomata with uncomplicated recovery. Aged 18, 66 4 recurrent cardiac myxomata including a right ventricular and two left ventricular tumors were once again resected 67 and a goretex patch was placed in the right ventricular wall. In the immediate post-operative period, he suffered 68 ventricular tachycardia (VT) and cardiac arrest with spontaneous return of circulation. At this time, a genetics 69 evaluation suggested the possibility of Carney complex but clinical genetic testing (sequencing of PRKAR1A) was 70 negative for disease causing variation. At age 19, multiple thyroid nodules were noted on ultrasound, and he was 71 also diagnosed with ACTH-independent Cushing's syndrome, secondary to the adrenal microadenoma. At 21, he 72 underwent trans-sphenoidal resection of the pituitary tumor. At this time, he was found to have recurrent myxomata 73 in the left ventricular outflow tract that have subsequently increased in size (Figure 1B-C) . To date, these have been 74 treated conservatively with anti-coagulation to reduce the risk of stroke. As of 2016, he is under consideration for 75 heart transplantation and the transplant team judged a molecular diagnosis highly desirable prior to cardiac 76 transplant listing. As a result, whole genome SRS was performed. Genomic DNA was purified, and a library was 77 generated using the Illumina® TruSeq® DNA PCR-Free Library Prep Kit, and genome sequencing was performed 78 using the Illumina HiSeq® 2500 System with paired-end 2 x 100 bp reads to a 36-fold mean depth of coverage. The 79 data analysis and variant curation were performed by the Stanford Medicine Clinical Genomics Service. Single 80 nucleotide variants and small insertions and deletions were identified using MedGAP v2.0, a pipeline based on 81 GATK best practices for data pre-processing and variant discovery with GATK HaplotypeCaller v3.1.1. 8 This 82 analysis pipeline did not identify any variants that would explain the clinical findings in the patient. 83
To evaluate structural variation, low coverage whole genome LRS was performed on the PacBio Sequel™ system. 84
Following consent under a protocol approved by the Stanford University Institutional Review Board, DNA was 85 isolated from a peripheral blood specimen using the Gentra® Puregene® Blood Kit (Qiagen, Germantown, MD). 86
The DNA was sheared to 20 kb fragments on a Megaruptor® and size-selected to 10 kb using the Sage Science 87
BluePippin™ system. A SMRTbell™ library was prepared and sequenced on 10 Sequel SMRT Cells 1M with 88 chemistry S/P1-C1.2 and 6 hour collections. The sequencing yielded 26.7 Gb (8.6-fold coverage of human genome) 89 in 4.3 million reads with a read length N50 of 9,614 bp. Reads were mapped to the GRCh37/hg19 assembly of the 90 human genome using NGM-LR v0.1.4 with default parameters. 9 Structural variants were called using PBHoney 91 Spots with '-q 10 -m 10 -i 20 -e 1 -E 1 -spanMax 100000 -consensus None' for deletions and '-q 10 -m 70 -i 20 -92 e 2 -E 2 -spanMax 10000 -consensus None' for insertions. 10 Variant calls were further refined to retain only those 93 larger than 50 bp, supported by at least 20% of local reads, and at least 100 bp from an assembly gap. 94 5 The resulting call set consisted of 6,971 deletions and 6,821 insertions. To prioritize candidate pathogenic variants, 95 the call set was filtered to exclude variants within a segmental duplication or present in the unrelated control 96 individual NA12878 (A.W., unpublished data). This left 2,368 deletions and 3,174 insertions. Focusing on variants 97 that overlap a RefSeq coding exon resulted in 20 deletions and 16 insertions, with 3 deletions and 3 insertions in 98 genes tied to a genetic disease in OMIM (Table 1) . Manual review of the 6 candidate variants and correlation with 99 phenotype identified a heterozygous deletion that removes the first coding exon of PRKAR1A (NM_212472.2). 100
Germline variants in PRKAR1A cause Carney complex, type 1 (MIM #160980), an autosomal dominant multiple 101 neoplasia syndrome. 11 Two of four reads at the locus unambiguously support the presence of a deletion variant 102 (Figure 2A) . Because of the random errors in LRS, individual reads from the same allele can have slight 103 disagreements, and two reads can be insufficient to define exact deletion breakpoints with full confidence. Here, the 104 higher quality read supports a 2,184 bp deletion of GRCh37/hg19 chr17:66,510,475-66,512,658 105 (NC_000017.10:g.66510475_66512658del). This heterozygous deletion variant was validated by Sanger 106 sequencing, which in this case confirmed the precise breakpoints identified by LRS (Figure 2B) . 107
It is difficult to call structural variants in SRS data with simultaneously high sensitivity and specificity that is 108 necessary for clinical laboratory testing. Nevertheless, once a small candidate gene list or approximate breakpoints 109 are known, many variants can be identified retrospectively. 5 In such cases, SRS often provides exact breakpoints to 110 refine the variant discovered by LRS. 12 Manual inspection of SRS data from the PRKAR1A locus shows support for 111 the heterozygous deletion through a drop in read depth and alignment clipping at the deletion breakpoints ( Figure  112 2C). Multiple short-read structural variant callers, including Pindel, Lumpy, BreakDancer, Manta, CNVKit, and 113
CNVnator, were retrospectively used to identify structural variants. [13] [14] [15] [16] [17] [18] All tools were run with default parameters. 114
Pindel, Lumpy, BreakDancer, and Manta all identify a deletion in the locus. Pindel and Manta approximately match 115 the breakpoints identified from LRS and Sanger sequencing. 116
This case demonstrates the ability of whole genome LRS to detect causal structural variation in a rare disease, and to 117 our knowledge, this is the first reported application of whole genome LRS to identify a pathogenic variant in a 118 patient. Although manual inspection of the aligned read data and short-read structural variant callers are able to 119 identify this 2,184 bp deletion, these approaches are not practical to apply genome wide due to limited throughput 120 and high false-positive call rates, respectively. Looking forward, clinical-grade genomics demands strong precision 121 6 and recall across the full spectrum of genetic variation. SRS has limited sensitivity for variants larger than a few 122 base pairs, and it can miss up to 80% of the structural variants in an individual genome. 3 LRS appears to be capable 123 of identifying much of the missed variation, and manifests high recall of structural variants even at low depths of 124 coverage. 12 125
To accelerate the adoption of sequencing-based structural variant analysis into clinical practice, it will be important 126 for the community to develop and expand an ecosystem of tools and databases similar to that which has arisen 127 around smaller variants. We advocate further development and continued evaluation of tools and best practices for 128 calling structural variants from SRS, LRS and orthogonal data. Additionally, we recommend that the community 129 prioritize creation of a catalog of structural variation derived from these data sources. Databases of common single 130 nucleotide variation, such as ExAC, have proven incredibly valuable. 19 We expect that a comparable database of 131 structural variants would be similarly valuable and that building the database from LRS would greatly expand 132 current catalogs such as DGV and dbVar. 20,21 133 LRS has seen limited adoption in clinical genomics laboratories, in large part due to the per base error rate and cost. 134
Although the individual read error rate requires higher coverage to provide clinical-grade identification of single 135 nucleotide variants, high coverage is not necessarily required for sensitive and specific detection of larger structural 136 variants. Cost effectiveness will ultimately be judged not on cost per base, but on cost per diagnosis. Larger studies 137 on the diagnostic yield of various approaches using LRS will be required to answer the question of the most cost 138 effective technologies for clinical genomics moving forward. 139 was filtered to remove variants in segmental duplications or the NA12878 control and to focus on variants that 225 overlap coding exons of genes with a known link to genetic disease. 226
